
Jagsonpal Pharmaceuticals Ltd.
Stock Scores
93.8 / 100
38.1 / 100
77.1 / 100
88.5 / 100
Key Metrics
Stock Analysis
Fundamental analysis overview of Jagsonpal Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Strong price momentum
Price Momentum score of 77.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
77.1 / 100
High and improving operating margin
The company reported strong operating margin of 17.65% for 12-month ended 30 Jun 2026 and operating margin improved by 151 bps from 1 year ago
What is Operating profit margin?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.03 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 3 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Expensive and at a premium to industry median P/E
PE TTM of 35.17 indicates that the stock is expensive on a standalone basis and is at a 15.12% premium to industry median P/E
What is P/E Ratio?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of 3.87% for 12-month ended 30 Jun 2026 and the growth was 6.72 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -25.37% for 12-month ended 30 Jun 2026 and the growth was 32.57 percentage points lower than median growth of industry
What is EPS growth (1Y)?
High ROE but declining trend
The company reported strong ROE of 16.69% for 12-month ended 30 Jun 2026 but ROE declined by -922 bps from 1 year ago
What is ROE (FY)?
Company's earnings are of moderate quality
Earnings quality score of 64.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
64.8 / 100
Moderate dividend yield
The company has a moderate dividend yield of 1.65%
What is Dividend yield?
Financial Snapshot
See detailed analysisMulti-year trends for Jagsonpal Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Jagsonpal Pharmaceuticals Ltd. is not part of any tracked index.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Jagsonpal Pharmaceuticals Ltd. shares as reported to NSE and BSE.
| Name | Month | Transaction | Holding % pre transaction | Average price | Qty. | Transaction value |
|---|---|---|---|---|---|---|
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group | June-2022 | Off Market (Disposal) 29th Jun 2022 | 64.10 % | ₹ 235.00 | 1.15 cr | ₹ 269.20 cr |
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group | February-2022 | Market Sale (Disposal) 28th Feb 2022 | 64.94 % | ₹ 238.12 | 2.26 lac | ₹ 5.38 cr |
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group | February-2022 | Market Sale (Disposal) 25th Feb 2022 | 65.71 % | ₹ 234.15 | 2.00 lac | ₹ 4.68 cr |
INDERPAL SINGH KOCHHAR Designated Person | January-2021 | Market Purchase (Acquisition) 4th Jan 2021 | 0.21 % | ₹ 72.06 | 17.64 k | ₹ 12.71 lac |
Corporate Actions
History of Jagsonpal Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
- Dividend₹ 2.50/shareRecord date: 4th Sep 2026Ex-date: 4th Sep 2026Announced on: 27th Apr 2026
- Dividend₹ 1.50/shareRecord date: 4th Sep 2026Ex-date: 4th Sep 2026Announced on: 17th Aug 2026
- OthersEx-date: 4th May 2026Announced on: 12th Mar 2026"On Market Tender Offer."
- Dividend₹ 2.50/shareRecord date: 12th Sep 2025Ex-date: 12th Sep 2025Announced on: 6th May 2025
- Stock Split1 : 3Ex-date: 8th Jan 2025Announced on: 23rd Oct 2024Nominal Value change from INR 05 INR 02.
Company Profile
Overview of Jagsonpal Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.


